{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T17:58:47Z","timestamp":1783360727746,"version":"3.54.6"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T00:00:00Z","timestamp":1623974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T00:00:00Z","timestamp":1623974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s13555-021-00558-0","type":"journal-article","created":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T04:30:52Z","timestamp":1623990652000},"page":"1357-1372","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase\u00a03 Trials"],"prefix":"10.1007","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5371-4427","authenticated-orcid":false,"given":"Christopher","family":"Griffiths","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1249-6993","authenticated-orcid":false,"given":"Marjolein","family":"de Bruin-Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0593-9925","authenticated-orcid":false,"given":"Mette","family":"Deleuran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7249-2556","authenticated-orcid":false,"given":"Maria Concetta","family":"Fargnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4780-4212","authenticated-orcid":false,"given":"Delphine","family":"Staumont-Sall\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9963-8319","authenticated-orcid":false,"given":"Chih-ho","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1427-6003","authenticated-orcid":false,"given":"Jose","family":"S\u00e1nchez-Carazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5891-5607","authenticated-orcid":false,"given":"Peter","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2915-839X","authenticated-orcid":false,"given":"Seong Jun","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4733-5855","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"Msihid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7231-0054","authenticated-orcid":false,"given":"Sonya L.","family":"Cyr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5345-678X","authenticated-orcid":false,"given":"Ana B.","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,18]]},"reference":[{"issue":"10023","key":"558_CR1","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","volume":"387","author":"S Weidinger","year":"2016","unstructured":"Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109\u201322.","journal-title":"Lancet"},{"key":"558_CR2","doi-asserted-by":"crossref","unstructured":"Silverberg JI, Barbarot S, Gadkari A, et al. Atopic dermatitis in the pediatric population: a cross-sectional, international, epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):417\u2013428.e2.","DOI":"10.1016\/j.anai.2020.12.020"},{"issue":"6","key":"558_CR3","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1111\/all.13401","volume":"73","author":"S Barbarot","year":"2018","unstructured":"Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73(6):1284\u201393.","journal-title":"Allergy"},{"issue":"1","key":"558_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd4624","volume":"15","author":"NA Gandhi","year":"2016","unstructured":"Gandhi NA, Bennett BL, Graham NM, Pirozzi P, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type\u00a02 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35\u201350.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"558_CR5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/pde.13678","volume":"36","author":"LM LePoidevin","year":"2019","unstructured":"LePoidevin LM, Lee DE, Shi VY. A comparison of international management guidelines for atopic dermatitis. Pediatr Dermatol. 2019;36(1):36\u201365.","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"558_CR6","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/j.1346-8138.2004.tb00673.x","volume":"31","author":"M Furue","year":"2004","unstructured":"Furue M, Terao H, Moroi Y, et al. Dosage and adverse effects of topical tacrolimus and steroids in daily management of atopic dermatitis. J Dermatol. 2004;31(4):277\u201383.","journal-title":"J Dermatol"},{"issue":"1","key":"558_CR7","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1046\/j.1365-2133.2003.04934.x","volume":"148","author":"M Furue","year":"2003","unstructured":"Furue M, Terao H, Rikihisa W, et al. Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis. Br J Dermatol. 2003;148(1):128\u201333.","journal-title":"Br J Dermatol"},{"issue":"2","key":"558_CR8","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jaad.2010.01.035","volume":"64","author":"IM Haeck","year":"2011","unstructured":"Haeck IM, Rouwen TJ, Timmer-de Mik L, de Bruin-Weller MS, Bruijnzeel-Koomen CA. Topical corticosteroids in atopic dermatitis and the risk of glaucoma and cataracts. J Am Acad Dermatol. 2011;64(2):275\u201381.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"558_CR9","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1172\/JCI21060","volume":"113","author":"DY Leung","year":"2004","unstructured":"Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. J Clin Invest. 2004;113(5):651\u20137.","journal-title":"J Clin Invest"},{"issue":"4","key":"558_CR10","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1111\/bjd.16714","volume":"180","author":"LAA Gerbens","year":"2019","unstructured":"Gerbens LAA, Apfelbacher CJ, Irvine AD, et al. TREatment of ATopic eczema (TREAT) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo- and systemic therapy registries. Br J Dermatol. 2019;180(4):790\u2013801.","journal-title":"Br J Dermatol"},{"issue":"6","key":"558_CR11","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1111\/bjd.18959","volume":"183","author":"FM Vermeulen","year":"2020","unstructured":"Vermeulen FM, Gerbens LAA, Schmitt J, et al. The European TREatment of ATopic eczema (TREAT) Registry Taskforce survey: prescribing practices in Europe for phototherapy and systemic therapy in adult patients with moderate-to-severe atopic eczema. Br J Dermatol. 2020;183(6):1073\u201382.","journal-title":"Br J Dermatol"},{"key":"558_CR12","doi-asserted-by":"publisher","unstructured":"Alexander H, Patton T, Jabbar-Lopez ZK, Manca A, Flohr C. Novel systemic therapies in atopic dermatitis: what do we need to fulfil the promise of a treatment revolution? F1000Res. 2019;8(F1000 Faculty Rev):132. https:\/\/doi.org\/10.12688\/f1000research.17039.1.","DOI":"10.12688\/f1000research.17039.1"},{"issue":"2","key":"558_CR13","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jaci.2013.07.049","volume":"133","author":"E Roekevisch","year":"2014","unstructured":"Roekevisch E, Spuls PI, Kuester D, Limpens J, Schmitt J. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. J Allergy Clin Immunol. 2014;133(2):429\u201338.","journal-title":"J Allergy Clin Immunol"},{"key":"558_CR14","first-page":"P-161","volume":"81","author":"M de Bruin-Weller","year":"2019","unstructured":"de Bruin-Weller M, Pink AE, Patrizi A, et al. EUROSTAD prospective observational study: baseline characteristics, atopic dermatitis severity, and patient-reported outcomes. J Am Acad Dermatol. 2019;81:P-161.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"558_CR15","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.jaad.2010.02.062","volume":"63","author":"C Ryan","year":"2010","unstructured":"Ryan C, Amor KT, Menter A. The use of cyclosporine in dermatology: part II. J Am Acad Dermatol. 2010;63(6):949\u201374.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"558_CR16","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","volume":"71","author":"R Sidbury","year":"2014","unstructured":"Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327\u201349.","journal-title":"J Am Acad Dermatol"},{"key":"558_CR17","unstructured":"European Medicines Agency. Assessment report for Sandimmun Neoral and associated names. 2013. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/sandimmun-neoral-article-30-referral-assessment-report_en.pdf. Accessed 18 Mar 2021."},{"issue":"4","key":"558_CR18","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/ajd.13314","volume":"61","author":"W Berry","year":"2020","unstructured":"Berry W, Daniel BS, Baker C, Foley P. Real world experience using ciclosporin in psoriasis: efficacy and toxicity in the Australasian Psoriasis Registry. Australas J Dermatol. 2020;61(4):380\u20132.","journal-title":"Australas J Dermatol"},{"issue":"2 Suppl","key":"558_CR19","doi-asserted-by":"publisher","first-page":"229S","DOI":"10.1016\/j.transproceed.2004.01.021","volume":"36","author":"A Busauschina","year":"2004","unstructured":"Busauschina A, Schnuelle P, van der Woude FJ. Cyclosporine nephrotoxicity. Transplant Proc. 2004;36(2 Suppl):229S-S233.","journal-title":"Transplant Proc"},{"issue":"6","key":"558_CR20","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.jaip.2017.08.005","volume":"5","author":"M Boguniewicz","year":"2017","unstructured":"Boguniewicz M, Alexis AF, Beck LA, et al. Expert perspectives on management of moderate-to-severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies. J Allergy Clin Immunol Pract. 2017;5(6):1519\u201331.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"558_CR21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.anai.2017.10.039","volume":"120","author":"M Boguniewicz","year":"2018","unstructured":"Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120(1):10-22.e2.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"558_CR22","doi-asserted-by":"publisher","first-page":"adv00402","DOI":"10.2340\/00015555-3751","volume":"101","author":"M Bruin-Weller","year":"2021","unstructured":"Bruin-Weller M, Biedermann T, Bissonnette R, et al. Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. Acta Dermato Venereolog. 2021;101(2):adv00402. https:\/\/doi.org\/10.2340\/00015555-3751.","journal-title":"Acta Dermato Venereolog"},{"issue":"14","key":"558_CR23","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.1073\/pnas.1323896111","volume":"111","author":"LE Macdonald","year":"2014","unstructured":"Macdonald LE, Karow M, Stevens S, et al. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci USA. 2014;111(14):5147\u201352.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"14","key":"558_CR24","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1073\/pnas.1324022111","volume":"111","author":"AJ Murphy","year":"2014","unstructured":"Murphy AJ, Macdonald LE, Stevens S, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci USA. 2014;111(14):5153\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"558_CR25","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","volume":"13","author":"NA Gandhi","year":"2017","unstructured":"Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4\/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425\u201337.","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"558_CR26","first-page":"S41","volume":"137","author":"A Armstrong","year":"2017","unstructured":"Armstrong A, Wei W, Garcia-Horton V, et al. Risk of contraindication and drug-drug interaction (DDI) with use of systemic immunosuppressants (IMMs) in adult patients with atopic dermatitis (AD). J Invest Dermatol. 2017;137(5):S41.","journal-title":"J Invest Dermatol"},{"issue":"24","key":"558_CR27","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase\u00a03 trials of dupilumab vs placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348.","journal-title":"N Engl J Med"},{"issue":"5","key":"558_CR28","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"M de Bruin-Weller","year":"2018","unstructured":"de Bruin-Weller M, Tha\u00e7i D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAF\u00c9). Br J Dermatol. 2018;178(5):1083\u20131101.","journal-title":"Br J Dermatol"},{"issue":"10086","key":"558_CR29","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase\u00a03 trial. Lancet. 2017;389(10086):2287\u2013303.","journal-title":"Lancet"},{"key":"558_CR30","unstructured":"European Medicines Agency. DUPIXENT\u00ae (dupilumab). Summary of product characteristics. Available from: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2019\/20190801145601\/anx_145601_en.pdf. Accessed 18 Mar 2021."},{"key":"558_CR31","unstructured":"US Food and Drug Administration. DUPIXENT\u00ae (dupilumab). Highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761055s014lbl.pdf. Accessed 18 Mar 2021."},{"issue":"1","key":"558_CR32","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jid.2016.07.012","volume":"137","author":"A Drucker","year":"2017","unstructured":"Drucker A, Wang A, Li W, Sevetson E, Block JK, Qureshi AA. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26\u201330.","journal-title":"J Invest Dermatol"},{"issue":"Suppl 1","key":"558_CR33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1159\/000370226","volume":"66","author":"C Lifschitz","year":"2015","unstructured":"Lifschitz C. The impact of atopic dermatitis on quality of life. Ann Nutr Metab. 2015;66(Suppl 1):34\u201340.","journal-title":"Ann Nutr Metab"},{"issue":"10","key":"558_CR34","doi-asserted-by":"publisher","first-page":"851","DOI":"10.2340\/00015555-3219","volume":"99","author":"LFM Ari\u00ebns","year":"2019","unstructured":"Ari\u00ebns LFM, Gadkari A, van Os-Medendorp H, et al. Dupilumab vs cyclosporine for the treatment of moderate-to-severe atopic dermatitis in adults: indirect comparison using the Eczema Area and Severity Index. Acta Derm Venereol. 2019;99(10):851\u20137.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"558_CR35","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.3390\/jcm9061982","volume":"9","author":"DH Jang","year":"2020","unstructured":"Jang DH, Heo SJ, Jung HJ, Park MY, Seo SJ, Ahn JY. Retrospective study of dupilumab treatment for moderate to severe atopic dermatitis in Korea: efficacy and safety of dupilumab in real-world practice. J Clin Med. 2020;9(6):1982.","journal-title":"J Clin Med"},{"issue":"4","key":"558_CR36","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.jaad.2020.08.127","volume":"84","author":"LF Ari\u00ebns","year":"2021","unstructured":"Ari\u00ebns LF, van der Schaft J, Spekhorst LS, et al. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-weeks results from the Dutch BioDay registry. J Am Acad Dermatol. 2021;84(4):1000\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"558_CR37","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1111\/all.14324","volume":"75","author":"LS Spekhorst","year":"2020","unstructured":"Spekhorst LS, Ari\u00ebns LFM, van der Schaft J, et al. Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: results from the BioDay registry. Allergy. 2020;75(9):2376\u20139.","journal-title":"Allergy"},{"key":"558_CR38","doi-asserted-by":"publisher","unstructured":"Fargnoli MC, Esposito M, Ferrucci S, et al. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis. J Dermatolog Treat. 2019. https:\/\/doi.org\/10.1080\/09546634.2019.1682503.","DOI":"10.1080\/09546634.2019.1682503"},{"issue":"6","key":"558_CR39","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.aller.2019.12.005","volume":"48","author":"M Giavina-Bianchi","year":"2020","unstructured":"Giavina-Bianchi M, Rizzo L, Giavina-Bianchi P. Severe atopic dermatitis: Dupilumab is not just safer, but more efficient. Allergol Immunopathol (Madr). 2020;48(6):792\u20137.","journal-title":"Allergol Immunopathol (Madr)"},{"issue":"3","key":"558_CR40","doi-asserted-by":"publisher","first-page":"791","DOI":"10.3390\/jcm9030791","volume":"9","author":"S Ferrucci","year":"2020","unstructured":"Ferrucci S, Casazza G, Angileri L, et al. Clinical response and quality of life in patients with severe atopic dermatitis treated with dupilumab: a single-center real-life experience. J Clin Med. 2020;9(3):791.","journal-title":"J Clin Med"},{"issue":"4","key":"558_CR41","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40257-020-00527-x","volume":"21","author":"LA Beck","year":"2020","unstructured":"Beck LA, Tha\u00e7i D, Deleuran M, et al. Dupilumab provides favorable safety and sustained efficacy for up to 3 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2020;21(4):567\u201377.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"558_CR42","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jaad.2020.05.003","volume":"84","author":"JF Merola","year":"2021","unstructured":"Merola JF, Sidbury R, Wollenberg A, et al. Dupilumab prevents flares in adults with moderate-to-severe atopic dermatitis in a 52-week randomized controlled phase\u00a03 trial. J Am Acad Dermatol. 2021;84(2):495\u20137.","journal-title":"J Am Acad Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-021-00558-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-021-00558-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-021-00558-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T16:41:21Z","timestamp":1628613681000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-021-00558-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,18]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["558"],"URL":"https:\/\/doi.org\/10.1007\/s13555-021-00558-0","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,18]]},"assertion":[{"value":"31 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Error in the graphical abstract corrected and replaced with updated version","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}